Analyst Ratings For AIT Therapeutics (NASDAQ:AITB)
Today, Roth Capital initiated coverage on AIT Therapeutics (NASDAQ:AITB) with a Buy with a price target of $14.00.
There are 3 buy ratings on the stock.
The current consensus rating on AIT Therapeutics (NASDAQ:AITB) is Buy (Score: 3.00) with a consensus target price of $15.00 per share, a potential 160.87% upside.
Some recent analyst ratings include
- 9/25/2017-Roth Capital initiated coverage with a Buy rating.
- 8/24/2017-Laidlaw initiated coverage with a Buy rating.
- 8/7/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
Recent Trading Activity for AIT Therapeutics (NASDAQ:AITB)
Shares of AIT Therapeutics closed the previous trading session at with shares trading hands.